tralokinumab
Selected indexed studies
- Tralokinumab. (, 2006) [PMID:35073030]
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). (Br J Dermatol, 2021) [PMID:33000465]
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. (Health Technol Assess, 2024) [PMID:38343072]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. (2024) pubmed
- Tralokinumab. (2006) pubmed
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). (2021) pubmed
- Tralokinumab. (2012) pubmed
- Tralokinumab (Adbry ®). (1994) pubmed
- Tralokinumab: First Approval. (2021) pubmed
- Tralokinumab in Atopic Dermatitis: A Profile of Its Use. (2022) pubmed
- Tralokinumab in atopic dermatitis. (2021) pubmed
- Tralokinumab (Adbry®). (1994) pubmed
- Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. (2019) pubmed